Blockade of Sphingosine-1- Phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization

X. I E Bing, Jikui Shen, Aling Dong, Aymen Rashid, Glenn Stoller, Peter A Campochiaro

Research output: Contribution to journalArticle

Abstract

Sphingosine-1-phosphate (SIP) is a bioactive lipid molecule that stimulates endothelial cell migration, proliferation, and survival in vitro, and tumor angiogenesis in vivo. In this study, we used a humanized monoclonal antibody (sonepcizumab) that selectively binds SIP to investigate its role in retinal and choroidal neovascularization (NV). Intraocular injection of sonepcizumab significantly reduced macrophage influx into ischemic retina and strongly suppressed retinal NV in mice with oxygen-induced ischemic retinopathy. In mice with laser-induced rupture sites in Bruch's membrane, intraocular injection of sonepcizumab significantly reduced the area of choroidal NVand concomitantly reduced fluorescein leakage from the remaining choroidal NV. Four weeks after intraocular injection of up to I.8 mg of the sonepcizumab in non-human primates, electroretinograms and fluorescein angiograms were normal, and light microscopy of ocular sections showed no evidence of structural damage. These data show for the first time that SIP stimulates both choroidal and retinal NV and suggest that sonepcizumab could be considered for evaluation in patients with choroidal or retinal NV.

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalJournal of Cellular Physiology
Volume218
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Retinal Neovascularization
Choroidal Neovascularization
Macrophages
Intraocular Injections
Fluorescein
Antibodies, Monoclonal, Humanized
Endothelial cells
Bruch Membrane
Optical microscopy
Tumors
Primates
Oxygen
Cell Movement
Membranes
Lipids
Retina
Rupture
Microscopy
Cell Survival
Angiography

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Blockade of Sphingosine-1- Phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization. / Bing, X. I E; Shen, Jikui; Dong, Aling; Rashid, Aymen; Stoller, Glenn; Campochiaro, Peter A.

In: Journal of Cellular Physiology, Vol. 218, No. 1, 01.2009, p. 192-198.

Research output: Contribution to journalArticle

@article{f9283fe5c0d54712a5ab82bc8552c5fd,
title = "Blockade of Sphingosine-1- Phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization",
abstract = "Sphingosine-1-phosphate (SIP) is a bioactive lipid molecule that stimulates endothelial cell migration, proliferation, and survival in vitro, and tumor angiogenesis in vivo. In this study, we used a humanized monoclonal antibody (sonepcizumab) that selectively binds SIP to investigate its role in retinal and choroidal neovascularization (NV). Intraocular injection of sonepcizumab significantly reduced macrophage influx into ischemic retina and strongly suppressed retinal NV in mice with oxygen-induced ischemic retinopathy. In mice with laser-induced rupture sites in Bruch's membrane, intraocular injection of sonepcizumab significantly reduced the area of choroidal NVand concomitantly reduced fluorescein leakage from the remaining choroidal NV. Four weeks after intraocular injection of up to I.8 mg of the sonepcizumab in non-human primates, electroretinograms and fluorescein angiograms were normal, and light microscopy of ocular sections showed no evidence of structural damage. These data show for the first time that SIP stimulates both choroidal and retinal NV and suggest that sonepcizumab could be considered for evaluation in patients with choroidal or retinal NV.",
author = "Bing, {X. I E} and Jikui Shen and Aling Dong and Aymen Rashid and Glenn Stoller and Campochiaro, {Peter A}",
year = "2009",
month = "1",
doi = "10.1002/jcp.21588",
language = "English (US)",
volume = "218",
pages = "192--198",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Blockade of Sphingosine-1- Phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization

AU - Bing, X. I E

AU - Shen, Jikui

AU - Dong, Aling

AU - Rashid, Aymen

AU - Stoller, Glenn

AU - Campochiaro, Peter A

PY - 2009/1

Y1 - 2009/1

N2 - Sphingosine-1-phosphate (SIP) is a bioactive lipid molecule that stimulates endothelial cell migration, proliferation, and survival in vitro, and tumor angiogenesis in vivo. In this study, we used a humanized monoclonal antibody (sonepcizumab) that selectively binds SIP to investigate its role in retinal and choroidal neovascularization (NV). Intraocular injection of sonepcizumab significantly reduced macrophage influx into ischemic retina and strongly suppressed retinal NV in mice with oxygen-induced ischemic retinopathy. In mice with laser-induced rupture sites in Bruch's membrane, intraocular injection of sonepcizumab significantly reduced the area of choroidal NVand concomitantly reduced fluorescein leakage from the remaining choroidal NV. Four weeks after intraocular injection of up to I.8 mg of the sonepcizumab in non-human primates, electroretinograms and fluorescein angiograms were normal, and light microscopy of ocular sections showed no evidence of structural damage. These data show for the first time that SIP stimulates both choroidal and retinal NV and suggest that sonepcizumab could be considered for evaluation in patients with choroidal or retinal NV.

AB - Sphingosine-1-phosphate (SIP) is a bioactive lipid molecule that stimulates endothelial cell migration, proliferation, and survival in vitro, and tumor angiogenesis in vivo. In this study, we used a humanized monoclonal antibody (sonepcizumab) that selectively binds SIP to investigate its role in retinal and choroidal neovascularization (NV). Intraocular injection of sonepcizumab significantly reduced macrophage influx into ischemic retina and strongly suppressed retinal NV in mice with oxygen-induced ischemic retinopathy. In mice with laser-induced rupture sites in Bruch's membrane, intraocular injection of sonepcizumab significantly reduced the area of choroidal NVand concomitantly reduced fluorescein leakage from the remaining choroidal NV. Four weeks after intraocular injection of up to I.8 mg of the sonepcizumab in non-human primates, electroretinograms and fluorescein angiograms were normal, and light microscopy of ocular sections showed no evidence of structural damage. These data show for the first time that SIP stimulates both choroidal and retinal NV and suggest that sonepcizumab could be considered for evaluation in patients with choroidal or retinal NV.

UR - http://www.scopus.com/inward/record.url?scp=58149166482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149166482&partnerID=8YFLogxK

U2 - 10.1002/jcp.21588

DO - 10.1002/jcp.21588

M3 - Article

C2 - 18781584

AN - SCOPUS:58149166482

VL - 218

SP - 192

EP - 198

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 1

ER -